Combination Therapies for Hepatocellular Carcinoma

Combination therapy for advanced hepatocellular carcinoma: do we ...

Although the median overall survival (mOS) was not reached in the combination therapy group, it was significantly longer than the 13.2-month mOS in the ...

Combination Therapies for Hepatocellular Carcinoma | Radiology

The Barcelona Clinic Liver Cancer (BCLC) model outlines clinical practice guidelines based on the patient's tumor burden, liver disease, and ...

Combined treatments in hepatocellular carcinoma: Time to put them ...

EMERALD-2 is an ongoing A Phase III, multicenter study of Durvalumab monotherapy or in combination with Bevacizumab as adjuvant therapy in patients with HCC who ...

Combination immunotherapy for hepatocellular carcinoma

Immunotherapy combinations tested in phase III trials include ICIs and bevacizumab, ICIs and tyrosine kinase inhibitors, and the combination of ...

Updates on Systemic Therapy for Hepatocellular Carcinoma

Ongoing trials exploring combinations with immunotherapy and multikinase inhibitors indicate a shift toward multidrug regimens in first-line HCC ...

Radiation Therapy With Combination Therapy of Immune ...

Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have limited efficacy in treating advanced hepatocellular carcinoma ...

Precision combination therapies: shaping the future management of ...

For example, chemotherapy has been shown to stimulate a sensitizing effect upon tumor cells to immunotherapy (9), while the vascular remodeling effect of ...

Immune-based combination therapies for advanced HCC | JHC

Recently, dual immune checkpoint blockade with durvalumab plus tremelimumab has also emerged as an effective first-line treatment for advanced ...

Targeted therapy for hepatocellular carcinoma - Nature

Since sorafenib and TACE are both recommended therapies for advanced HCC, it is reasonable to expect that their combined use would confer ...

Recent advances in systemic therapy for hepatocellular carcinoma

Since small molecular inhibitors can at least partially reverse immune dysfunction, the combination of tivozanib and ICIs is a promising option.

Systemic treatment of hepatocellular carcinoma: from sorafenib to ...

In this review, we summarize current data on systemic treatment of patients with advanced HCC, focusing on combination therapies comprising immune checkpoint ...

A combination therapy to keep hepatocellular carcinoma in check

The combination of atezolizumab (an immune checkpoint inhibitor) and bevacizumab (antibody against VEGF) led to better overall and progression-free survival ...

Combination Therapies Outperform Sorafenib in Hepatocellular ...

After progression to first line, sorafenib and lenvatinib are recommended, with regorafenib (Stivarga), cabozantinib (Cabometyx), and ...

Cabozantinib-based combination therapy for the treatment of ... - Gut

Objective Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer with limited treatment options.

Combination therapies for advanced hepatocellular carcinoma

The combination of atezolizumab plus bevacizumab followed by regorafenib and atezolizumab plus bevacizumab followed by cabozantinib appears promising but ...

Advancements in Immunotherapeutic Treatments for Hepatocellular ...

Thus, it is still being investigated in ongoing clinical trials. Combination therapies with multiple drugs have demonstrated potential benefits in terms of ...

Review Challenges of combination therapy with immune checkpoint ...

ICI therapy is also an attractive approach for new drug development in hepatocellular carcinoma (HCC). For anti-PD-1 ICI, both nivolumab and pembrolizumab were ...

Combination of interventional oncology local therapies and ...

Interventional oncology (IO) local therapies of hepatocellular carcinoma (HCC) can activate anti-cancer immunity and it is potentially leading ...

Nivolumab plus ipilimumab combination therapy in patients with ...

Hepatocellular carcinoma (HCC), which accounts for 75%-85% of primary liver cancers,.

Challenges of combination therapy with immune checkpoint ...

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; PFS, progression-free survival; OS, overall survival; RFS, recurrence-free survival; TACE, ...